Aplastic Anemia: Severity, Symptoms, and Treatment Options

Aplastic anemia is a rare but serious condition in which the bone marrow fails to produce enough new blood cells. This deficiency affects all three blood cell lines: red blood cells (causing anemia), white blood cells (leading to leukopenia), and platelets (resulting in thrombocytopenia).

Symptoms

Symptoms vary depending on which cell lines are most affected:

  • Anemia: Fatigue, weakness, shortness of breath, pale skin, dizziness, and cold hands/feet.
  • Leukopenia: Increased susceptibility to infections, frequent fevers, and slow wound healing.
  • Thrombocytopenia: Easy bruising, prolonged bleeding from minor cuts, nosebleeds, bleeding gums, and petechiae (tiny red/purple spots on skin).

Severe cases can be life-threatening due to overwhelming infection or uncontrolled bleeding.

Causes and Risk Factors

Aplastic anemia can be acquired or inherited. Acquired causes include autoimmune disorders, exposure to certain chemicals (benzene, pesticides), radiation, chemotherapy, viral infections (hepatitis, Epstein-Barr, HIV), and medications. Inherited forms include Fanconi anemia and dyskeratosis congenita.

Diagnosis

Diagnosis involves blood tests (complete blood count showing pancytopenia), bone marrow biopsy (hypocellular marrow with fat replacement), and tests to rule out other causes.

Treatment Options

Treatment depends on severity, age, and underlying cause:

  • Supportive care: Blood and platelet transfusions, antibiotics for infections, growth factors (G-CSF, erythropoietin).
  • Immunosuppressive therapy (IST): Anti-thymocyte globulin (ATG) plus cyclosporine is standard for non-transplant candidates or those without a matched donor.
  • Hematopoietic stem cell transplant (HSCT): Curative for eligible patients, especially younger individuals with a matched donor.
  • Eltrombopag: A thrombopoietin receptor agonist added to IST or used in refractory cases.

Prognosis

With modern treatment, many patients achieve remission. Five-year survival exceeds 70-80% with IST and 80-90% with matched sibling HSCT. Regular monitoring is essential due to risk of relapse and late clonal evolution (MDS, leukemia).

Blood Disorders - Related Articles